Question 1

How will the PET scan help in monitoring my treatment with erlotinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI) clinical trial (NCT02043002). Contact the study team or your healthcare provider for specific answers.

Question 2

What specific changes on the scan are important for predicting my response?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI) clinical trial (NCT02043002). Contact the study team or your healthcare provider for specific answers.

Question 3

Are there any risks or side effects from the PET scan I should know about?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI) clinical trial (NCT02043002). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to have these scans during my treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI) clinical trial (NCT02043002). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if the scan shows that the treatment is not working?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI) clinical trial (NCT02043002). Contact the study team or your healthcare provider for specific answers.

What this study is about